news
Majority retain COVID-19 antibodies for six months after infection
A study has shown that 88 percent of people infected by COVID-19 were able to produce SARS-CoV-2 antibodies after six months.
List view / Grid view
Antibodies
news
N439K variant of SARS-CoV-2 is resistant to some neutralising antibodies, shows study
The N439K mutation improves the interaction between SARS-CoV-2 Spike protein and the viral receptor ACE2 and eludes antibody-mediated immunity, say investigators.
news
Altering balance of fibroblasts could prevent spread of colorectal cancer
Researchers have found that colorectal cancer-associated fibroblasts can be altered using a gremlin 1-neutralising antibody or by overexpressing meflin.
whitepaper
Whitepaper: Why BioPharma Lifecycle Management?
In this whitepaper we explore some of the major bottlenecks in the development lifecycle and the current barriers to effective digital transformation.
whitepaper
Application note: Automated Simple Westerns in targeted protein degradation
Learn how Simple Western automated immunoassays screen degraders and IMiD compounds to quantify degradation activity, providing accurate DC50 and Dmax values.
news
Novel antibody candidate could offer pan-coronavirus protection
The lead candidate, ADG2, was able to neutralise SARS-CoV and various strains of SARS-CoV-2, including those that are resistant to currently available antibody treatments.
news
NSAIDs could be damaging to COVID-19 patients, dependent on timing, suggests study
In murine models of COVID-19, researchers found that non-steroidal anti-inflammatory drugs (NSAIDs) can suppress the inflammatory response and production of antibodies.
news
Rhesus macaques with SARS-CoV-2 develop promising immune response
A study has shown that the immune response of rhesus macaques with SARS-CoV-2 could be reproduced with a vaccine.
whitepaper
Application note: Evaluation of different ion-pairing reagents for LC/UV and LC/MS analysis of oligonucleotides
The effect of various ion pairing reagents (amines and acidic counterions) on the LC/UV and LC/MS analysis of oligonucleotides (ONs) has been studied.
news
SARS-CoV-2 triggers antibodies from previous coronavirus infections
A new study has shown that previous coronavirus infection may contribute to the immune response of patients infected with SARS-CoV-2.
webinar
High content screening reveals the phenotypic landscape of intestinal organoid regeneration
21 January 2021 | By Yokogawa Life Innovations
Watch our on-demand webinar and learn how image-based phenotypic screening relies on extraction of multivariate information from cells cultured in a large number of screened conditions. In this webinar, we explore the application of complex and biologically relevant model systems for drug screening, such as small intestinal organoids.
news
Novel nanobody combinations protect cells from SARS-CoV-2 in vitro
By combining nanobodies targeting different regions of the SARS-CoV-2 Spike protein, researchers were able to protect cells from infection.
news
Study shows how to improve cancer treatment with anti-OX40 antibodies
New insights into the mechanisms of anti-OX40 antibodies could enable their therapeutic activity to be manipulated to treat different tumours.
video
Webinar: Novel flow cytometry ACE-2 blocking assay
This webinar from Bio-Techne demonstrates how to use a novel in vitro flow cytometry-based assay to monitor SARS-CoV-2 binding to ACE-2.
news
2B7 antibody could be the breakthrough needed for dengue fever therapies
Scientists show that an antibody targeting a protein acting as a viral toxin, can prevent the dengue virus from infecting human cells.
